

## The Board of Directors approves the new Procedure relating to transactions with related parties of the Company

Pisa, 29<sup>th</sup> June 2021 – [PharmaNutra S.p.A.](#) (MTA; Ticker PHN), company specialised in the mineral-based nutritional supplements sector and medical devices for muscles and joints, informs that the Company's Board of Directors approved, with the positive opinion of the Independent Directors, members of the Control, Risks and Related Parties Committee, the new Procedure governing the completion of transactions with related parties of the Company, in compliance with the provisions of Consob Resolution no. 21624 of 10<sup>th</sup> December 2020, which amended Regulation no. 17221 of 12<sup>th</sup> March 2010, containing provisions on transactions with related parties, will come into force on 1<sup>st</sup> July 2021.

The Board of Directors also approved the new procedure for the internal management of Relevant Information and Price Sensitive Information and the public disclosure of Price Sensitive Information as well as the procedure for managing the register of persons who have access to Relevant Information and Price Sensitive Information.

The new procedures are available on the Company's website at [www.pharmanutra.it](http://www.pharmanutra.it), in the section Governance / Company Documents.

**PharmaNutra S.p.A.**

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative medical devices, handling the entire production process, from proprietary raw materials to the finished product. The effectiveness of its products is documented by considerable scientific proof, including 140 publications. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 150 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 39 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

[PharmaNutra.it](http://PharmaNutra.it)

For further information:

**PharmaNutra S.p.A.**

Via Delle Lenze, 216/b - 56122 Pisa  
Tel. +39 050 7846500

[investorrelation@PharmaNutra.it](mailto:investorrelation@PharmaNutra.it)

Internal Press Office

[press@calabughi.com](mailto:press@calabughi.com)

**Press Office - Spriano Communication & Partners**

Via Santa Radegonda, 16 - 20121 Milan  
Tel. +39 02 83635708

Matteo Russo

[mrusso@sprianocommunication.com](mailto:mrusso@sprianocommunication.com)

Cristina Tronconi

[ctronconi@sprianocommunication.com](mailto:ctronconi@sprianocommunication.com)